Gilead initiates Phase 3 clinical program for tenofovir alafenamide
24 January 2013 | By Gilead Sciences
“We are pleased to move TAF into Phase 3 clinical research...”
List view / Grid view
24 January 2013 | By Gilead Sciences
“We are pleased to move TAF into Phase 3 clinical research...”
7 January 2013 | By Gilead Sciences
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...
12 December 2012 | By Gilead Sciences
Gilead Sciences and YM BioSciences announced that the companies have signed a definitive agreement...
10 December 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that its Board of Directors has approved a two-for-one stock split...
27 November 2012 | By Gilead Sciences, Inc.
Gilead Sciences announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread®...
27 November 2012 | By Gilead Sciences
Gilead Sciences announced topline results from the Phase 3 POSITRON study...
15 November 2012 | By Gilead Sciences
STaR study findings support Complera as an important single tablet regimen option...
15 November 2012 | By Gilead Sciences
Two-year results announced ...
31 October 2012 | By Gilead Sciences
Data support tenofovir alafenamide fumarate as component of future single tablet HIV regimens...
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
2 August 2012 | By Gilead Sciences, Inc.
Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into agreements...
24 July 2012 | By Gilead Sciences, Inc.
Full clinical trial results from a pivotal Phase 3 study...
16 July 2012 | By Gilead Sciences
The U.S. FDA has approved once-daily oral Truvada®...
28 June 2012 | By Gilead Sciences
Gilead Sciences has submitted a New Drug Application to the U.S. FDA for marketing approval of cobicistat...
27 June 2012 | By Gilead Sciences Inc
Elvitegravir is also a component of Quad single tablet regimen...